Table 2.
Presents the pharmacokinetics of levofloxacin for plasma (n = 7), inflamed and healthy subcutaneous adipose tissue (n = 6). Data are shown as mean ± SD and (95% confidence intervals)
| Compartment | AUC(0,10 h) tissue : AUC(0,10 h) free plasma ratio | AUC(0,10 h) (mg l−1 h) | AUC(0,24 h) (mg l−1 h) plasma | Cmax (mg l−1) | tmax (h) | t½β (h) | CL (l h−1 kg−1) | Vz (l kg−1) |
|---|---|---|---|---|---|---|---|---|
| Plasma, total | — | 32.3 ± 7.3 | 52.1 ± 17.3 | 8.37 ± 1.93 | 0.52 ± 0.26 | 10.0 ± 6.3 | 0.12 ± 0.05 | 1.35 ± 0.30 |
| (n = 7) | (25.5–39.1) | (36.0–68.1) | (6.6–10.2) | (0.28–0.77) | (4.2–16.0) | (0.07–0.16) | (1.08–1.63) | |
| Tissue Inflamed | 1.15 ± 0.95 | 25.5 ± 16.8 | 5.45 ± 3.74 | 1.06 ± 0.14 | ||||
| (n = 6) | (0.15–2.15) | (7.9–43.1) | n.d. | (1.53–9.37) | (0.91–1.20) | n.d. | n.d. | n.d. |
| Tissue Healthy | 1.06 ± 0.61 | 23.5 ± 10.0 | 4.42 ± 2.09 | 1.39 ± 1.29 | ||||
| (n = 6) | (0.43–1.70) | (13.0–33.9) | n.d. | (2.22–6.61) | (0.04–2.74) | n.d. | n.d. | n.d. |
n.d: not determined.